Genetix Biotherapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Genetix Biotherapeutics, Inc. - overview
Established
1993
Location
Somerville, MA, US
Primary Industry
Pharmaceuticals
About
Founded in 1993 and based in Massachusetts, US, Genetix Biotherapeutics, Inc. fka Bluebird Bio, Inc. operates as a biotechnology company that develops and provides gene therapy, cancer immunotherapy, and gene editing platforms to cure patients with genetic and rare diseases.
Current Investors
Carlyle Group, SK Capital, TVM Capital Life Science
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.genetixbiotx.com
Verticals
HealthTech
Company Stage
Mature
Total Amount Raised
Subscriber access only
Genetix Biotherapeutics, Inc. - timeline of key events
Genetix Biotherapeutics, Inc. - financials
| Fiscal Year Ended | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 20,181,000 | 25,421,000 | 14,079,000 | 6,155,000 | 35,427,000 | 54,579,000 | 44,674,000 | 250,734,000 | 3,662,000 | - | - | - |
| % Revenue Growth (YoY) | - | 26.0% | (44.6%) | (56.3%) | 475.6% | 54.1% | (18.1%) | 461.3% | (98.5%) | - | - | - |
| EBITDA (USD) | (24,006,000) | (56,398,000) | (161,618,000) | (258,182,000) | (318,627,000) | (554,865,000) | (797,392,000) | (603,690,000) | (571,262,000) | - | - | - |
| Operating Income (USD) | (24,947,000) | (60,626,000) | (169,037,000) | (267,830,000) | (332,165,000) | (572,023,000) | (814,826,000) | (623,046,000) | (590,911,000) | - | - | - |
| Operating Margin | (123.6%) | (238.5%) | (1200.6%) | (4351.4%) | (937.6%) | (1048.1%) | (1823.9%) | (248.5%) | (16136.3%) | - | - | - |
| % EBITDA Margin | (119.0%) | (221.9%) | (1147.9%) | (4194.7%) | (899.4%) | (1016.6%) | (1784.9%) | (240.8%) | (15599.7%) | - | - | - |
| NET Income (USD) | (25,321,000) | (48,709,000) | (166,783,000) | (263,507,000) | (335,643,000) | (555,625,000) | (789,608,000) | (618,695,000) | (819,378,000) | - | - | - |
| % Net Margin | (125.5%) | (191.6%) | (1184.6%) | (4281.2%) | (947.4%) | (1018.0%) | (1767.5%) | (246.8%) | (22375.2%) | - | - | - |
Genetix Biotherapeutics, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Public to Private | Completed | Genetix Biotherapeutics, Inc. | - |
Displaying 1 - 1 of 1
Genetix Biotherapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.